Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Takayuki Yoshino, Atsuo Takashima et al.|The Lancet Oncology|2024Cited by 124
<scp>FGFR</scp>2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers <i>in vitro</i>Yongjun Cha, Tae‐You Kim|Molecular Oncology|2018Cited by 33